Business Context and Reporting Period
Company: BioMarin Pharmaceutical Inc.
Filing Type: Form 8-K (Current Report)
Report Date: October 27, 2025
Reporting Period: Third quarter ended September 30, 2025
This filing announces the Company's financial results for the third quarter of 2025. The detailed results are contained in a press release attached as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text serves as a cover document referencing the press release for specific data. Consequently, the filing text does not provide clear values for the following metrics:
- Revenue
- Profit (Net Income/Loss)
- Cash Flow
- Margins
- Debt and Liquidity
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not contain specific guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are expected to be found in the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for actual Q3 2025 revenue and earnings figures.
- Verify year-over-year and quarter-over-quarter growth rates in the attached press release.
- Check for any updated full-year 2025 guidance provided in the press release.
- Confirm the status of key product launches or regulatory approvals mentioned in the full report.